Chupak Louis, Wichroski Michael, Zheng Xiaofan, Ding Min, Martin Scott, Allard Christopher, Shi Jianliang, Gentles Robert, Meanwell Nicholas A, Fang Jie, Tenney Daniel, Tokarski John, Cao Carolyn, Wee Susan
Bristol Myers Squibb Research and Early Development, 100 Binney Street, Cambridge, Massachusetts 02142, United States.
Bristol Myers Squibb Research and Early Development, PO Box 4000, Princeton, New Jersey 08543-4000, United States.
ACS Med Chem Lett. 2023 Jun 12;14(7):929-935. doi: 10.1021/acsmedchemlett.3c00063. eCollection 2023 Jul 13.
We describe a phenotypic screening and optimization strategy to discover compounds that block intracellular checkpoint signaling in T-cells. We identified dual DGKα and ζ inhibitors notwithstanding the modest similarity between α and ζ relative to other DGK isoforms. Optimized compounds produced cytokine release and T-cell proliferation consistent with DGK inhibition and potentiated an immune response in human and mouse T-cells. Additionally, lead inhibitor demonstrated dose-dependent immune stimulation in the mouse OT-1 model, setting the stage for a drug discovery program.
我们描述了一种表型筛选和优化策略,以发现可阻断T细胞内检查点信号传导的化合物。尽管相对于其他DGK亚型,α和ζ之间的相似性不大,但我们仍鉴定出了双DGKα和ζ抑制剂。优化后的化合物产生了与DGK抑制作用一致的细胞因子释放和T细胞增殖,并增强了人和小鼠T细胞中的免疫反应。此外,先导抑制剂在小鼠OT-1模型中表现出剂量依赖性的免疫刺激作用,为药物发现计划奠定了基础。